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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 
Clinical characteristics and management 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
11.12.2020 Genetic 
mechanisms 
of critical 
illness in 
COVID-19  
Nature | 
article 
• Host-mediated lung 
inflammation can lead to 
death in critically ill patients 
with COVID-19 
• A study of more than 2,244 
critically ill patients from 208 
intensive care units in UK 
hospitals has identified 
specific host genetic 
variants associated with key 
host antiviral defence 
mechanisms and mediators 
of inflammatory organ 
damage resulting in 
increased susceptibility to 
severe COVID-19 
symptoms 
• Both mechanisms identified 
could be treated with 
existing drugs 
• To be explored through 
large-scale randomised 
clinical trials 
Genetics 
11.12.2020 Rapid triage 
for COVID-
19 using 
The Lancet 
Digital Health 
| Article 
• Early clinical presentation of 
COVID-19 can be difficult to 
distinguish from other 
illnesses with SARS-CoV-2 
PCR test results taking up 
Triage 
Infection Prevention and Control 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
10.12.2020 Global 
mobility and 
the threat of 
pandemics: 
evidence 
from three 
centuries 
CGD | 
Working 
Paper 
• Predictions are tested 
across four global 
pandemics in three different 
centuries 
• In all cases, reduction in 
pre-pandemic international 
mobility is associated with 
later arrival and no 
detectable reduction in final 
mortality 
• The case for permanent 
limits on international 
mobility to reduce the harm 
of future pandemics is weak 
Internation
al travel 
restrictions 
07.12.2020 Effect of 
internationall
y imported 
cases on 
internal 
spread of 
COVID-19: 
a 
mathematic
The Lancet 
Public Health 
| Article 
• This study considers the 
risk of case importation 
across 162 countries, in the 
context of local epidemic 
growth rates 
• Estimates are produced on 
a global scale to allow the 
complex relationship 
between the prevalence of 
COVID-19, traveller 
volume, and incidence 
locally to be combined, 
Internation
al travel 
restrictions 
routine 
clinical data 
for patients 
attending 
hospital: 
developmen
t and 
prospective 
validation of 
an artificial 
intelligence 
screening 
test 
to 72h for operational 
reasons 
• Here, this study shows two 
early-detection models for 
COVID-19 performing as 
effectively as a screening 
test for COVID-19 in 
patients attending the 
emergency department, 
excluding the illness with 
high-confidence by use of 
clinical data routinely 
available within 1h of 
presentation to hospital 
• A rapidly scalable 
approach, fitting within 
existing laboratory testing 
infrastructure and standard 
of care of hospitals in high-
income and middle-income 
countries 
al modelling 
study 
producing a simple metric 
that can be used to inform 
decisions about 
international travel 
restrictions where these 
make large contributions to 
slowing local transmission, 
and where they have little 
effect 
• In any countries, imported 
cases would make a 
relatively small contribution 
to local transmission, so 
travel restrictions would 
have very little effect on 
epidemics 
• Countries where travel 
restrictions would have a 
large effect on local 
transmission are those with 
strong travel links to 
countries with high COVID-
19 prevalence or countries 
that have successfully 
managed to control their 
local outbreaks 
Therapeutics 
Publication 
date 
Title/URL Journal/Article 
type 
Summary             Keywords 
14.12.2020 Azithromyci
n in 
hospitalised 
patients with 
COVID-19 
(RECOVER
Y): a 
randomised, 
controlled, 
open-label, 
platform trial 
medRxiv | 
pre-print (not 
peer 
reviewed) 
• In patients hospitalised 
with COVID-19, 
azithromycin did not 
provide any clinical benefit 
• 28 mortality 19% vs 19% 
(rate ratio 1.00 [95% CI 
0.90, 1.12]) 
• No effect on secondary 
outcomes either 
• An important negative 
result for minimising 
unnecessary antibiotic 
use to avoid resistance 
(unless a clear clinical 
indication to use) 
• Note results apply to 
hospitalised patients and 
await results from other 
trials to see if there is 
benefit in use outside of 
the hosptial 
Azithromycin, 
hospitalised 
patients 
11.12.2020 Baricitinib 
plus 
remdesivir 
for 
hospitalized 
adults with 
Covid-19  
NEJM | article 
• A double-blind, 
randomised, placebo-
controlled trial evaluation 
baricitinib plus remdesivir 
in hospitalised adults with 
COVID-19 
• Baricitinib plus remdesivir 
was superior to remdesivir 
alone reducing recovery 
time and accelerating 
improvement in clinical 
status among patients 
with Covid-19, notably 
among those receiving 
high-flow oxygen or 
noninvasive ventilation 
• The combination was 
associated with fewer 
serious adverse events 
Baricitinib, 
remdesivir, 
hospitalised 
patients 
08.12.2020 Hydroxychlo
roquine as 
postexposur
e 
prophylaxis 
to prevent 
severe 
acute 
respiratory 
syndrome 
coronavirus 
2 infection: a 
randomized 
trial 
Annals of 
Internal 
Medicine | 
Original 
Research  
• Household-randomized, 
double-blind, controlled 
trial of hydroxychloroquine 
postexposure prophylaxis 
in close contacts recently 
exposed (<96 hours) to 
persons with diagnosed 
SARS-CoV-2 infection 
• Hydroxychloroquine did 
not prevent SARS-CoV-2 
infection when taken as a 
postexposure prophylaxis 
Hydroxychloro
quine, 
postexposure, 
prophylaxis 
Vaccines 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
10.12.2020 Safety and 
efficacy of 
the 
BNT162b2 
mRNA 
Covid-19 
vaccine 
NEJM | 
Original 
research 
• Ongoing multinational, 
placebo-controlled, 
observer-blinded, 
pivotal efficacy trial of 
the BioNTech and 
Pfizer vaccine 
candidate 
• 43, 548 >=16y 
participants underwent 
randomisation, of 
whom 43,448 received 
BioNTech/Pfizer 
vaccine, safety, 
efficacy 
two-dose injections 21 
days apart of either 
placebo or the 
BNT162b2 vaccine 
candidate 
• A two-dose regimen of 
BNT162b2 conferred 
95% (95% credible 
interval 90.3, 97.6; 8 
cases of Covid-19 with 
onset at least 7 days 
after the second dose 
in participants 
assigned to receive 
BNT162b2 and 162 
cases among those 
who received placebo) 
protection against 
Covid-19 in persons 16 
years of age or older 
• Similar vaccine efficacy 
was observed across 
subgroups defined by 
age, sex, race, 
ethnicity, baseline 
body-mass index, and 
the presence of 
coexisting conditions 
• Safety over a median 
of 2 months was 
similar to that of other 
viral vaccine 
10.12.2020 Phase 1-2 
trial of a 
SARS-CoV-
2 
recombinant 
spike 
protein 
nanoparticle 
vaccine 
NEJM | 
Original 
Article 
• Randomised, placebo-
controlled, phase 1-2 
trial to evaluate the 
safety and 
immunogenicity of the 
rSARS-CoV-2 vaccine 
candidate NVX-
CoV2373 in two doses, 
with or without matrix-
M1 adjuvant in 131 
healthy adults 
• At 35 days, NVX-
CoV2373 appeared to 
be safe and elicited 
immune responses that 
exceeded levels in 
Covid-19 convalescent 
serum 
NVX-CoV2373, 
vaccine 
candidate, 
phase 1-2 trial 
08.12.2020 Safety and 
efficacy of 
the 
ChAdOx1 
Lancet | 
Article 
• Pooled interim analysis 
of four trials on the 
safety and efficacy of 
the ChAdOx1 nCoV-19 
vaccine 
Oxford vaccine, 
safety, efficacy 
nCoV-19 
vaccine 
(AZD1222) 
against 
SARS-CoV-
2: an interim 
analysis of 
four 
randomised 
controlled 
trials in 
Brazil, 
South 
African, and 
the UK 
• ChAdOx1 nCoV-19 
has an acceptable 
safety profile and has 
been found to be 
efficacious against 
symptomatic COVID-
19, with no hospital 
admissions or severe 
cases reported in the 
ChAdOx1 nCoV-19 
arm 
• In participants who 
received two standard 
doses, vaccine efficacy 
was 62.1% (95% CI 
41.0, 75.7; 27 [0.6%] of 
4440 in the ChAdOx1 
nCoV-19 group vs 71 
[1.6%] of 4455 in the 
control group) 
• In participants who 
received a low dose 
followed by a standard 
dose, vaccine efficacy 
was 90.0% (95% CI 
67.4, 97.0; 3 [0.2%] of 
1367 in the ChAdOx1 
nCoV-19 group vs 30 
[2.2%] of 1374 in the 
control group) 
• The vaccine can be 
stored and distributed 
at 2-8oC, suitable for 
global distribution 
• These positive results 
support regulatory 
submissions for 
conditional or 
emergency use of 
ChAdOx1 nCoV-19 
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type 
14.12.2020 The ethics of continuing placebo in SARS-
CoV-2 vaccine trials  
JAMA | Viewpoint 
13.12.2020 Nigeria: Where COVID-19 has left Nigeria’s 
heath system 
The Conversation Africa| Blog 
13.12.2020 Any delay in ending COVID could spur a 
different pandemic  
Scientific American 
12.12.2020 Facing up to long COVID  The Lancet | Editorial 
11.12.2020 Coronavirus vaccine update with Anthony 
Fauci  
JAMA Q&A 
10.12.2020 Reimagining India’s health system: a Lancet 
Citizens’ Commission 
The Lancet | Comment  
10.12.2020 The COVID-19 vaccines rush: participatory 
community engagement matters more than 
ever 
The Lancet | Comment 
10.12.2020 Restricting mobility will not stop the next 
pandemic  
CGD | Blog 
10.12.2020 A tale of two crises and the solutions that bind 
them: wild polio and COVID-19  
Forbes 
09.12.2020 A step backwards in the fight against global 
vaccine inequities 
The Lancet | Correspondence 
09.12.2020 From governance to community surveillance: 
Assam’s 360 degree COVID-19 response 
WHO | News 
08.12.2020 Oxford-AstraZeneca COVID-19 vaccine 
efficacy 
The Lancet | Comment 
07.12.2020 COVID-19 an violence against women and 
children: a third research round up for the 16 
days of activism 
CGD | Notes 
07.12.2020 The COVID-19 vaccine: do we know enough 
to end the pandemic? 
CGD | Notes 
Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Summary 
25.06.2020 Support for 
Rehabilitation: self-
management after 
COVID-19 related 
illness 
  
• WHO is planning to update this 
guidance and resources for 
clinical management of COVID-
19 to include long COVID 
   
 
Dashboards & Trackers1 
Cases & deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living evidence 
& policy maps 
Current research 
including trials 
  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa Ghana COVID-NMA WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard African 
Arguments 
Indonesia  EPPI Centre  WHO 
International 
Clinical Trials 
Registry 
Platform 
(ICTRP)  
 FIND SARS-CoV-
2 Diagnostics: 
performance data 
  US NIH 
registered 
clinical trials 
Vaccine 
Centre 
LSHTM 
Johns Hopkins 
University 
European 
CDC 
Nigeria CDC Norwegian 
Institute of 
Public Health 
Cytel  Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 
 
1 Listings of Dashboards & Trackers, C19 Resource Hubs and Online learning & Events is cumulative. New additions today are highlighted in green. Where events have 
happened in the past links are provided to recordings where available. 
WEF   Sierra Leone   Oxford C19 
Government 
Response 
Tracker 
(OxCGRT) 
US NIH  Our World in 
Data: C19 Testing 
  COVID-19 
Therapeutics 
Accelerator 
 COVID-19 
Vaccine 
Tracker 
Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence       
Global 5050    UK  IFPRI COVID-
19 Policy 
Response Portal 
Cochrane        
CEBM, 
University of 
Oxford 
  US  COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful 
     WHO COVID-
19 Database 
        
LSHTM               
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
C19 Resource Hubs 
 Global  Regional & 
Country 
Academic 
journals & 
Publishers 
Institutes/Centres/Funders/Other Health Topics   Social Sciences 
WHO COVID-19 
pandemic  
Africa CDC Annals of 
Internal 
Medicine 
LSTM Stop TB Partnership    SSHAP 
WHO risk 
communication  
African Union BMJ LSHTM 
 
  IDA 
WHO Q&A  Nigeria CDC Bulletin of the 
WHO  
ICL MRC Centre for Global 
Infectious Disease Analysis  
Global Menstrual 
Collective  
  Disability and 
inclusion 
WHO Global 
research  
GeoPoll: SSA Cambridge 
University Press 
ODI SLH: Handwashing in 
low resource settings 
  Coregroup IDDC 
COVID-19 
Solidarity Response 
Fund  
Global Health 
Network Africa 
Cell Press Johns Hopkins University RBM Partnership   Ethics, health 
systems & COVID-19 
UN African Academy 
of Sciences 
Cochrane  Center for Global Development  Epidemic 
Preparedness 
Innovations 
  Social Development 
Direct C19 blog series 
UN Women  Africa Evidence 
Network  
Elsevier CMMID Repository     
UNOCHA OCHA Southern 
and Eastern 
Africa COVID-19 
Digest  
Health Policy 
and Planning  
Norwegian Institute of Public 
Health  
    
UNHCR   South African 
Government 
JAMA Network  Oxford Centre for Evidence-
based Medicine  
    
UNICEF   The Lancet   HEART     
UNESCO    medRxiv and 
bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources and Analyses 
of C19 Impact 
    
World Bank   SAGE journals  Prevent Epidemics      
Our World in Data   Science       
COVID-19 
Narratives by David 
Nabarro 
  Springer Nature        
Reliefweb   SSRN 
(Preprints)  
      
Humanitarian 
OpenStreetMap 
Team 
  Wiley       
Global Partnership 
for Sustainable 
Development Data 
  
 
      
WorldPop           
Flowminder            
COVID-END            
Premise COVID-19 
Global Impact 
Study 
    
  
GISAID           
Online learning & events 
 Date Title/URL Online learning/event Duration Lead 
04.12.2020 COVID-19, supply chain resilience and 
global trade  
Webinar 1h CGD 
03.12.2020 More money for health services: What is the 
tole of PFM in the “new normal”?  
WHO & CGD Health 
systems Governance 
& Financing 
1h 30 Joe Kutzin 
01.12.2020 Solutions and support for the mental 
wellbeing of community health workers on 
the COVID-19 frontline  
Webinar   HSG TWG on CHWs with The 
George Institute for Global Health 
19.11.2020 Looking at the pandemic with a gender lens Live Twitter 
conversation 
  SSHAP 
16.11.2020 HIFA and WHO collaborate to promote 
sharing of experience and expertise around 
the maintenance of essential health services 
during (and after) the pandemic 
4-week discussion 
starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine predictions part 2: 
estimating the time before we approve 
efficacious COVID-19 vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global Public Health Response  Online event 1h30 CGD 
02.10.2020 Understanding and Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the Economic and Health Impact 
of COVID-19 across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, open-access learning 
platform for health emergencies, now offers 
10 online courses related to COVID19. 
Online courses Varies WHO 
Available now Standard precautions: Environmental 
cleaning and disinfection 
Online course 1 hour WHO 
Available now COVID-19: Effective Nursing in Times of 
Crisis 
Online course 2 weeks – 2 
hours per week 
Johns Hopkins School of Nursing 
Available now WHO Academy and WHO Info mobile 
applications 
Mobile app   WHO 
Available now COVID-19: Pandemics, Modelling and 
Policy 
Online learning 2 weeks | 2 hours 
weekly study 
FutureLearn UNESCO UNITWIN 
Complex Systems Digital 
Campus/Open University 
11.5.2020 COVID-19 Contact Tracing course Online learning 5 hours Johns Hopkins Bloomberg 
School of Health 
7-28 May 
2020 
Virtual Evidence Weeks  5 sessions 1h 30 International Initiative for Impact 
Evaluation (3ie) 
Tuesdays at 
1700 CEST 
(Geneva time) 
& Thursdays 
0830 CEST 
(Geneva time) 
COVID-19 Open online brief with Dr David 
Nabarro 
Event 1h 4SD 
Available now Emerging respiratory viruses, including 
COVID-19: methods for detection, 
prevention, response and control 
Online learning 3 hours WHO 
Available now Responding to COVID-19: Real-time training 
for the coronavirus disease outbreak  
Online learning Multiple self-
paced course 
WHO 
25 May 2020 COVID-19: Tackling the Novel Coronavirus Online learning 3 weeks | 4 hours 
weekly study 
FutureLearn LSHTM/UK PHRST 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 Diagnostics and Testing Online learning 3 weeks | 3 hours 
weekly study 
FutureLearn FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical Care: Understanding and 
Application 
Online learning 5 weeks | 1 hour 
weekly study 
FutureLearn University of 
Edinburgh & Royal College of 
Physicians of Edinburgh  
Available now COVID-19 supporting online courses Online learning Multiple self-
paced course 
BMJ Learning 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before making 
decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D 
consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. 
K4D services are provided by a consortium of leading organisations working in international development, led by 
the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield 
Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of 
Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and 
Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
© Crown copyright 2020. 
